• Pharma firm looks to parallel chromatography to speed development
    ViroPharma is using parallel chromatography to accelerate its pharma development process

Bioanalytical

Pharma firm looks to parallel chromatography to speed development

Jun 25 2010

The development process of new pharma solutions by ViroPharma is being accelerated thanks to its use of parallel chromatography.

Using the parallel chromatography procedure, the pharma firm explains that it is able to double the capacity of its manufacturing line by running across multiple shifts.

On May 26th, ViroPharma disclosed that it had supplied Cinryze manufactured through the parallel chromatography process for use in patients with hereditary angioedema.

Now it has filed a Prior Approval Supplement with the US Food and Drug Administration to allow it to commercialise the drug manufactured through the industrial scale process.

The request hinges on industrial-scale production of the drug matching the quality of the previous scale in use.

ViroPharma says that it has the data to demonstrate this being the case and expects to see approval granted by the end of the year.

Cinryze is an injectible medicine which tackles hereditary angioedema by preventing painful attacks and helping to reduce the risk of swelling.

Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions

Events

Korea Lab 2024

Apr 23 2024 Kintex, South Korea

Korea Chem 2024

Apr 23 2024 Seoul, South Korea

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

ChemUK 2024

May 15 2024 Birmingham, UK

View all events